Committee Action
On June 14, 2023, the Subcommittee on Health held a hearing
on H.R. 3391. The Subcommittee received testimony from:
Dr. Elizabeth Cherot, MD, MBA, Senior Vice
President and Chief Medical Health Officer, March of
Dimes;
Dr. Alexis A. Thompson, MD, MPH, Chief of
Division of Hematology, Elias Schwartz MD Endowed Chair
in Hematology, Children's Hospital of Philadelphia,
Professor of Pediatrics, University of Pennsylvania
Perelman School of Medicine;
Dr. Meredithe McNamara, MD, MS, FAAP,
Assistant Professor, Yale School of Medicine;
Dr. Miriam Grossman, MD, Child, Adolescent,
and Adult Psychiatrist;
Mr. George Manahan, Parkinson's Advocate and
Patient; and,
Mr. Kevin O'Connor, Assistant to the General
President for Government Affairs and Political Action,
International Association of Fire Fighters.
On, July 13, 2023, the Subcommittee on Health met in open
markup session and forwarded H.R. 3391, as amended, to the full
Committee by a record vote of 27 yeas and 0 nays. On July 19,
2023, the full Committee on Energy and Commerce met in open
markup session and ordered H.R. 3391, as amended, favorably
reported to the House by a record vote of 50 yeas and 0 nays.
Congressional Budget Office Estimate
Pursuant to clause 3(c)(3) of rule XIII, at the time this
report was filed, the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974 was not available.
Federal Mandates Statement
The Committee adopts as its own the estimate of Federal
mandates prepared by the Director of the Congressional Budget
Office pursuant to section 423 of the Unfunded Mandates Reform
Act.
Statement of General Performance Goals and Objectives
Pursuant to clause 3(c)(4) of rule XIII, the general
performance goal or objective of this legislation is to
facilitate research and education around the relationship
between childhood cancer and structural birth defects by
reauthorizing funding for the National Institute of Health's
Gabriella Miller Kids First Pediatric Research Program and
coordinating federal efforts related to pediatric cancer
research.
Duplication of Federal Programs
Pursuant to clause 3(c)(5) of rule XIII, no provision of
H.R. 3391 is known to be duplicative of another Federal
program, including any program that was included in a report to
Congress pursuant to section 21 of Public Law 111-139 or the
most recent Catalog of Federal Domestic Assistance.
Related Committee and Subcommittee Hearings
Pursuant to clause 3(c)(6) of rule XIII, the following
related hearing was used to develop or consider H.R. 3391:
On June 14, 2023, the Subcommittee on Health
held a hearing on H.R. 3391. The Subcommittee received
testimony from:
Dr. Elizabeth Cherot, MD, MBA,
Senior Vice President and Chief Medical Health
Officer, March of Dimes;
Dr. Alexis A. Thompson, MD, MPH,
Chief of Division of Hematology, Elias Schwartz
MD Endowed Chair in Hematology, Children's
Hospital of Philadelphia, Professor of
Pediatrics, University of Pennsylvania Perelman
School of Medicine;
Dr. Meredithe McNamara, MD, MS,
FAAP, Assistant Professor, Yale School of
Medicine;
Dr. Miriam Grossman, MD, Child,
Adolescent, and Adult Psychiatrist;
Mr. George Manahan, Parkinsons
Advocate and Patient; and,
Mr. Kevin O'Connor, Assistant to
the General President for Government Affairs
and Political Action, International Association
of Fire Fighters.
Committee Cost Estimate
Pursuant to clause 3(d)(1) of rule XIII, the Committee
adopts as its own the cost estimate prepared by the Director of
the Congressional Budget Office pursuant to section 402 of the
Congressional Budget Act of 1974. At the time this report was
filed, the estimate was not available.
Earmark, Limited Tax Benefits, and Limited Tariff Benefits
Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the
Committee finds that H.R. 3391 contains no earmarks, limited
tax benefits, or limited tariff benefits.
Advisory Committee Statement
No advisory committees within the meaning of section 5(b)
of the Federal Advisory Committee Act were created by this
legislation.
Applicability to Legislative Branch
The Committee finds that the legislation does not relate to
the terms and conditions of employment or access to public
services or accommodations within the meaning of section
102(b)(3) of the Congressional Accountability Act.
Section-by-Section Analysis of the Legislation
Section 1. Short title
Section 1 provides a short title of ``Gabriella Miller Kids
First Research Act 2.0''.
Section 2. Funding for the pediatric research initiative
Section 2 amends section 402 of the Public Health Service
Act to extend funding for the Division of Program Coordination,
Planning, and Strategic Initiatives for fiscal years 2024
through 2028.
Section 3. Coordination of NIH funding for pediatric research
Section 3 expresses the sense of Congress that the Director
of the National Institutes of Health oversee and coordinate
pediatric research supported by the NIH and amends section 402
of the Public Health Service Act to clarify pediatric research
should not duplicate existing research activities of the NIH.
Section 4. Report on progress and investment in pediatric research
Section 4 directs the Secretary of Health and Human
Services to submit a report no later than 5 years after the
bill's enactment detailing current federally funded pediatric
research programs and initiatives and advancements made.
Changes in Existing Law Made by the Bill, as Reported
In compliance with clause 3(e) of rule XIII of the Rules of
the House of Representatives, changes in existing law made by
the bill, as reported, are shown as follows (existing law
proposed to be omitted is enclosed in black brackets, new
matter is printed in italics, and existing law in which no
change is proposed is shown in roman):
PUBLIC HEALTH SERVICE ACT
* * * * * * *
TITLE IV--NATIONAL RESEARCH INSTITUTES
Part A--National Institutes of Health
* * * * * * *
appointment and authority of director of nih
Sec. 402. (a) The National Institutes of Health shall be
headed by the Director of NIH who shall be appointed by the
President by and with the advice and consent of the Senate. The
Director of NIH shall perform functions as provided under
subsection (b) and as the Secretary may otherwise prescribe.
(b) In carrying out the purposes of section 301, the
Secretary, acting through the Director of NIH--
(1) shall carry out this title, including being
responsible for the overall direction of the National
Institutes of Health and for the establishment and
implementation of general policies respecting the
management and operation of programs and activities
within the National Institutes of Health;
(2) shall coordinate and oversee the operation of the
national research institutes, national centers, and
administrative entities within the National Institutes
of Health;
(3) shall, in consultation with the heads of the
national research institutes and national centers, be
responsible for program coordination across the
national research institutes and national centers,
including conducting priority-setting reviews, to
ensure that the research portfolio of the National
Institutes of Health is balanced and free of
unnecessary duplication, and takes advantage of
collaborative, cross-cutting research;
(4) shall assemble accurate data to be used to assess
research priorities, including--
(A) information to better evaluate scientific
opportunity, public health burdens, and
progress in reducing health disparities; and
(B) data on study populations of clinical
research, funded by or conducted at each
national research institute and national
center, which--
(i) specifies the inclusion of--
(I) women;
(II) members of minority
groups;
(III) relevant age
categories, including pediatric
subgroups; and
(IV) other demographic
variables as the Director of
the National Institutes of
Health determines appropriate;
(ii) is disaggregated by research
area, condition, and disease
categories; and
(iii) is to be made publicly
available on the Internet website of
the National Institutes of Health;
(5) shall ensure that scientifically based strategic
planning is implemented in support of research
priorities as determined by the agencies of the
National Institutes of Health, and through the
development, implementation, and updating of the
strategic plan developed under subsection (m);
(6) shall ensure that the resources of the National
Institutes of Health are sufficiently allocated for
research projects identified in strategic plans;
(7)(A) shall, through the Division of Program
Coordination, Planning, and Strategic Initiatives--
(i) identify research that represents
important areas of emerging scientific
opportunities, rising public health challenges,
or knowledge gaps that deserve special emphasis
and would benefit from conducting or supporting
additional research that involves collaboration
between 2 or more national research institutes
or national centers, or would otherwise benefit
from strategic coordination and planning;
(ii) include information on such research in
reports under section 403; and
(iii) in the case of such research supported
with funds referred to in subparagraph (B)--
(I) require as appropriate that
proposals include milestones and goals
for the research;
(II) require that the proposals
include timeframes for funding of the
research; and
(III) ensure appropriate
consideration of proposals for which
the principal investigator is an
individual who has not previously
served as the principal investigator of
research conducted or supported by the
National Institutes of Health;
(B)(i) may, with respect to funds reserved under
section 402A(c)(1) for the Common Fund, allocate such
funds to the national research institutes and national
centers for conducting and supporting research that is
identified under subparagraph (A); and
(ii) shall, with respect to funds appropriated to
[the Common Fund] the Division of Program Coordination,
Planning, and Strategic Initiatives pursuant to section
402A(a)(2), allocate such funds to the national
research institutes and national centers for making
grants for pediatric research that is identified under
subparagraph (A) and shall prioritize, as appropriate,
such pediatric research that does not duplicate
existing research activities of the National Institutes
of Health; and
(C) may assign additional functions to the Division
in support of responsibilities identified in
subparagraph (A), as determined appropriate by the
Director;
(8) shall, in coordination with the heads of the
national research institutes and national centers,
ensure that such institutes and centers--
(A) preserve an emphasis on investigator-
initiated research project grants, including
with respect to research involving
collaboration between 2 or more such institutes
or centers;
(B) when appropriate, maximize investigator-
initiated research project grants in their
annual research portfolios;
(C) foster collaboration between clinical
research projects funded by the respective
national research institutes and national
centers that--
(i) conduct research involving human
subjects; and
(ii) collect similar data; and
(D) encourage the collaboration described in
subparagraph (C) to--
(i) allow for an increase in the
number of subjects studied; and
(ii) utilize diverse study
populations, with special consideration
to biological, social, and other
determinants of health that contribute
to health disparities;
(9) shall ensure that research conducted or supported
by the National Institutes of Health is subject to
review in accordance with section 492 and that, after
such review, the research is reviewed in accordance
with section 492A(a)(2) by the appropriate advisory
council under section 406 before the research proposals
are approved for funding;
(10) shall have authority to review and approve the
establishment of all centers of excellence recommended
by the national research institutes;
(11)(A) shall oversee research training for all of
the national research institutes and National Research
Service Awards in accordance with section 487; and
(B) may conduct and support research training--
(i) for which fellowship support is not
provided under section 487; and
(ii) that does not consist of residency
training of physicians or other health
professionals;
(12) may, from funds appropriated under section
402A(b), reserve funds to provide for research on
matters that have not received significant funding
relative to other matters, to respond to new issues and
scientific emergencies, and to act on research
opportunities of high priority;
(13) may, subject to appropriations Acts, collect and
retain registration fees obtained from third parties to
defray expenses for scientific, educational, and
research-related conferences;
(14) for the national research institutes and
administrative entities within the National Institutes
of Health--
(A) may acquire, construct, improve, repair,
operate, and maintain, at the site of such
institutes and entities, laboratories, and
other research facilities, other facilities,
equipment, and other real or personal property,
and
(B) may acquire, without regard to the Act of
March 3, 1877 (40 U.S.C. 34), by lease or
otherwise through the Administrator of General
Services, buildings or parts of buildings in
the District of Columbia or communities located
adjacent to the District of Columbia for use
for a period not to exceed ten years;
(15) may secure resources for research conducted by
or through the National Institutes of Health;
(16) may, without regard to the provisions of title
5, United States Code, governing appointments in the
competitive service, and without regard to the
provisions of chapter 51 and subchapter III of chapter
53 of such title relating to classification and General
Schedule pay rates, establish such technical and
scientific peer review groups and scientific program
advisory committees as are needed to carry out the
requirements of this title and appoint and pay the
members of such groups, except that officers and
employees of the United States shall not receive
additional compensation for service as members of such
groups;
(17) may secure for the National Institutes of Health
consultation services and advice of persons from the
United States or abroad;
(18) may use, with their consent, the services,
equipment, personnel, information, and facilities of
other Federal, State, or local public agencies, with or
without reimbursement therefor;
(19) may, for purposes of study, admit and treat at
facilities of the National Institutes of Health
individuals not otherwise eligible for such treatment;
(20) may accept voluntary and uncompensated services;
(21) may perform such other administrative functions
as the Secretary determines are needed to effectively
carry out this title;
(22) may appoint physicians, dentists, and other
health care professionals, subject to the provisions of
title 5, United States Code, relating to appointments
and classifications in the competitive service, and may
compensate such professionals subject to the provisions
of chapter 74 of title 38, United States Code;
(23) shall designate a contact point or office to
help innovators and physicians identify sources of
funding available for pediatric medical device
development;
(24) implement the Cures Acceleration Network
described in section 480;
(25) may require recipients of National Institutes of
Health awards to share scientific data, to the extent
feasible, generated from such National Institutes of
Health awards in a manner that is consistent with all
applicable Federal laws and regulations, including such
laws and regulations for the protection of--
(A) human research participants, including
with respect to privacy, security, informed
consent, and protected health information; and
(B) proprietary interests, confidential
commercial information, and the intellectual
property rights of the funding recipient;
(26) shall consult with the Assistant Secretary for
Preparedness and Response, the Director of the
Biomedical Advanced Research and Development Authority,
the Director of the Centers for Disease Control and
Prevention, and the heads of other Federal agencies and
offices, as appropriate, regarding research needs to
advance medical countermeasures to diagnose, mitigate,
prevent, or treat harm from any biological agent or
toxin, including emerging infectious diseases,
chemical, radiological, or nuclear agent that may cause
a public health emergency or other research needs
related to emerging public health threats;
(27) shall consult with the Director of the Office of
National Security within the Department of Health and
Human Services, the Assistant Secretary for
Preparedness and Response, the Director of National
Intelligence, the Director of the Federal Bureau of
Investigation, and the heads of other appropriate
agenci